News
Policy Update: Homocysteine Testing
Fecha: 27/02/26
Effective May 1, 2026, there will be an update to Homocysteine Testing clinical policy. For additional information, please review Homocysteine Testing under the clinical policies.
Policy Number | Policy Name | Policy Description |
CP.MP.121 | Homocysteine Testing | Homocysteine is a nonproteinogenic amino acid generated during the conversion of methionine to cysteine. Mutations of the enzymes within the biochemical pathways that regulate homeostatic homocysteine levels are associated with risk factors for various diseases such as venous thromboembolic disease.18,19 Supplementation of folic acid, vitamin B6, and vitamin B12 are known to modulate homocysteine levels due to the interplay between the folate cycle and metabolism. This policy describes the medical necessity requirements for testing levels of homocysteine. |
If you have questions, please contact Provider Relations.